
The recommendation is backed by data from the phase 3 LITESPARK-011 trial.
Rana McKay, MD, discusses the next steps needed to advance the treatment paradigm for patients with advanced renal cell carcinoma. McKay is a medical oncologist and associate professor of medicine at the University of California San Diego, Moores Cancer Center.